KoBioLabs, Inc (KOSDAQ:348150)

KoBioLabs Statistics

Total Valuation

KoBioLabs has a market cap or net worth of KRW 115.15 billion. The enterprise value is 96.15 billion.

Market Cap	115.15B
Enterprise Value	96.15B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

KoBioLabs has 19.42 million shares outstanding. The number of shares has increased by 2.04% in one year.

Current Share Class	19.42M
Shares Outstanding	19.42M
Shares Change (YoY)	+2.04%
Shares Change (QoQ)	+0.99%
Owned by Insiders (%)	29.95%
Owned by Institutions (%)	0.07%
Float	13.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.66
PB Ratio	2.30
P/TBV Ratio	3.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.61
EV / Sales	1.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.07

Financial Position

The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.27.

Current Ratio	5.16
Quick Ratio	4.47
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	-2.00
Interest Coverage	-15.35

Financial Efficiency

Return on equity (ROE) is -15.66% and return on invested capital (ROIC) is -8.24%.

Return on Equity (ROE)	-15.66%
Return on Assets (ROA)	-5.78%
Return on Invested Capital (ROIC)	-8.24%
Return on Capital Employed (ROCE)	-11.38%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.70
Inventory Turnover	4.29

Taxes

Income Tax	-19.76M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.06% in the last 52 weeks. The beta is 0.69, so KoBioLabs's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-4.06%
50-Day Moving Average	5,450.20
200-Day Moving Average	5,136.60
Relative Strength Index (RSI)	56.05
Average Volume (20 Days)	1,453,669

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KoBioLabs had revenue of KRW 69.48 billion and -8.28 billion in losses. Loss per share was -427.79.

Revenue	69.48B
Gross Profit	51.02B
Operating Income	-9.19B
Pretax Income	-8.57B
Net Income	-8.28B
EBITDA	-6.43B
EBIT	-9.19B
Loss Per Share	-427.79

Balance Sheet

The company has 49.37 billion in cash and 13.70 billion in debt, giving a net cash position of 35.68 billion or 1,837.27 per share.

Cash & Cash Equivalents	49.37B
Total Debt	13.70B
Net Cash	35.68B
Net Cash Per Share	1,837.27
Equity (Book Value)	50.11B
Book Value Per Share	1,721.93
Working Capital	48.36B

Cash Flow

In the last 12 months, operating cash flow was -6.64 billion and capital expenditures -198.61 million, giving a free cash flow of -6.83 billion.

Operating Cash Flow	-6.64B
Capital Expenditures	-198.61M
Free Cash Flow	-6.83B
FCF Per Share	-351.96

Margins

Gross margin is 73.43%, with operating and profit margins of -13.23% and -11.92%.

Gross Margin	73.43%
Operating Margin	-13.23%
Pretax Margin	-12.33%
Profit Margin	-11.92%
EBITDA Margin	-9.26%
EBIT Margin	-13.23%
FCF Margin	n/a

Dividends & Yields

KoBioLabs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.04%
Shareholder Yield	n/a
Earnings Yield	-7.19%
FCF Yield	-5.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KoBioLabs has an Altman Z-Score of 0.02 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.02
Piotroski F-Score	5